[ Promentis Pharmaceuticals raises $26M in Series C ]
Promentis Pharmaceuticals has raised $26 million in Series C funding.
Founded in 2006, Promentis Pharmaceuticals is a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders.
This financing will enable Promentis to advance its lead compound SXC-2023 through Phase 2 clinical proof of concept. SXC-2023 is a novel small molecule designed to engage System Xc-, a CNS target addressing glutamatergic dysfunction and oxidative stress, with a compelling profile across a range of pre-clinical studies.
|Founder / CEO||Klaus Veitinger|
|Investors||Golden Triangle Angel Network|
|F-Prime Capital Partners|
|Black Pearl Capital Partners|
|Previous Investors||Golden Angels Investors|
|Black Horse Investments|
|National Institutes of Health|